Last updated: 2026/01/15
Homepage
Last updated: 2026/01/15
Home
Solutions
Clinical Operations
Enrollment
Biometrics
Data Management
Biostatistics
Statistical Programming
PK&PD
Medical Writing
Medical Monitoring
Strategic & Registration Affairs
Pharmacovigilance
Quality Assurance
Centralized Monitoring
Therapeutic Areas
Cell & Gene Therapy (CGT)
Endocrinology & Metabolism
Oncology
Rare Disease
Ophthalmology
Cardiovascular
Immunology & Inflammation
Dermatology
Neuroscience
Infectious Disease
Others
Capabilities
IIT
Early Phase Trials
Pivotal Trials
After-Approval Studies
Bioequivalence
Delivery Model
Consulting
FSP Solutions
Full Service Solutions
About
About Us
Company News
Functional Service Provider (FSP) Services
Pristine New Leader — Committed to Becoming a Trusted Global Clinical Research Solutions Provider
New Breakthrough! Pristine Pharma Assists Conber Pharma in Securing Approval for Novel Dry Eye Drug
China's First! Pristine Pharma Empowers Gensci's Groundbreaking Gout Drug to Market Success
Exhibitions & Events
Lancet-Validated Milestone: GCP ClinPlus' Biostatistics Team Elevates China's Influenza Drug Research onto the World Stage
National Respiratory Center Salutes GCP ClinPlus with Prestigious Research Award
Empowering 210+ Marketed Innovations: GCP ClinPlus Honored as ''Best Enabling Service Partner''
Industry News
CROs on Fire: Davis Double Play Has Arrived
CXO Sector: Valuation Re-rating Under Way
FDA Crackdown on Trial Design: What July's CRLs to Replimune and Capricor Mean for Sponsors
Insights
Regulatory Intelligence
China Accelerates Clinical Trials Approval to Just 30 Days
Cases & Articles
GCP ClinPlus: Pioneering China's First Stem Cell Therapy Approval
China's Drug Approval Landscape is Accelerating: Partner with GCP ClinPlus to Navigate this Dynamic Market
Accelerating Innovative Cancer Treatment to Approval Executive Summary
Case Study: Gene Therapy for Beta-Thalassemia (RM-001)
GCP ClinPlus Secures Series B Funding!
Study Kickoff Announcement | Treg Cell Therapy for ALS at Tiantan Hospital
Major Policy Boost for Innovative Drugs in China
FAQ: Conducting CGT Investigator-Initiated Trials (IITs) in China
Frequently Asked Questions: Clinical Operations in China for International Biopharmas
Why Global Biotechs are Turning to China for Clinical Trials: The Speed, Quality, and Cost Advantage
Global Biometrics Excellence: Powering Clinical Trial Success
Build or Buy? A Guide to Biometrics Resourcing
Interpreting the Roles and Responsibilities of Relevant Personnel from the Perspective of Clinical Trial Data Flow
Top 5 Biometrics Mistakes That Delay Clinical Trials
Checklist: How to Select a Biometrics Partner
Case Study: World's First 40kD Y-PEG Long-Acting Growth Hormone Approval
3 FDA Rejections You Can Avoid with Better Data Strategy
SDTM, ADaM or Define.XML: The Three Pillars of Data Standardization in Drug Development
Clinical Data Management Services
SAS Programming Services
Biostatistics Services
Biometrics in 2025: What Sponsors Need to Know Now
Avoiding Rework: How Intelligent Programming Saves Time in the Later Trial Phase
Navigating the Statistical Challenges of Rare Disease Clinical Trials
Case Study: Scalable Programming Excellence with FSP
Case Study: Strategic Clinical Oversight Accelerates Oncology Approval
Global Biometrics Excellence: A Decade-Long Partnership Driving Pharmaceutical Success
White Papers
China's CGT Market Opportunity: Accelerating Global Cell & Gene Therapy Development
Unlocking Opportunities: Ophthalmology Clinical Trials in China
China Hepatitis B and Liver Cancer Prevention and Treatment White Paper 2025
FAQs
Blog
Celebrating Another Milestone: Onradivir Tablets Approved
Why Partner with a China CRO for Global Cell and Gene Therapy Trials?
Unlocking Efficiency: A Guide to GCP ClinPlus's Clinical Operations Solutions
Mastering Compliance: GCP ClinPlus's Essential Guidelines for Clinical Data Management
Navigating Clinical Trials with Confidence: GCP ClinPlus's Phase-Specific Guidelines
GCP Insights – 7-Day Series | Key Updates: China's 2025 GCP Draft vs. 2020 Version (Day 1)
GCP Insights · Seven-Day Series | Is the 'Ethics Committee' Being Phased Out? 6 New Must-Know Terms for Day 1 (DAY 2)
GCP Insights · Seven-Day Series | Reshaping the Responsibilities of the Ethics Review Committee: Major Adjustments to Risk-Proportionate Review and Document Retention Periods (DAY 3)
GCP Insights · Seven-Day Series | Principal Investigator = The One to Blame? Decoding the Ultimate Responsibility Checklist with One Chart (DAY 4)
GCP Insights · Seven-Day Series | The Monitoring Chapter Vanishes: How to Write the Quality Management Plan in the RBM Era? (DAY 5)
GCP Insights · Seven-Day Series | A Brand-New Chapter is Born! GCP 2025 Establishes Principles for Data Lifecycle Management and Blinding Maintenance (DAY 6)
GCP Insights · Seven-Day Series | Streamlined Framework: GCP 2025 Shrinks from 9 Chapters & 83 Articles to 6 Chapters & 54 Articles – These Chapters Have Disappeared (DAY 7)
China's IIT Breakthrough: New Regulatory Clarity Opens Doors for Global Biopharma
GCP ClinPlus Named “Best Enabling Service Organization”
China Speed in CGT: From IND to NDA in 20 Months
China: A Competitive Destination for Global Radiopharmaceutical Clinical Trials
Reflecting on World Mental Health Day: Advancing Psychiatric Clinical Research with Compassion and Rigor
From the Lancet to NMPA Approval: GCP ClinPlus Accelerates Metabolic Drug Innovation
From Data to Approval: GCP ClinPlus Accelerates OT-702 with Al-Powered Execution
China's In Vivo CAR-T Landscape: Technology, Ecosystem, and Clinical Innovation Momentum
Expert Interview | Leveraging China's Clinical Resources to Build Faster, Smarter Global Clinical Trials
Expert Interview | Empowering Innovation, Navigating Complexity: GCP ClinPlus on the Statistical Science and Art of Anticancer Drug Clinical Trials
Videos
GCP ClinPlus Company Video
GCP GlinPlus Clinical Biometrics Service Introduction Video
Contact
RFI / RFP
Careers
Last updated: 2026/01/15
Last updated: 2026/01/15
